Latest Regulatory Development News

Cauldron Energy has outlined a substantial new uranium exploration target on recently acquired tenements adjacent to Paladin’s Manyingee deposit, underpinning Yanrey’s growing status as a major uranium province in Western Australia.

ASX Limited projects a significant 18-21% rise in expenses for FY27 driven by technology modernisation and regulatory response, while increasing capital expenditure guidance to up to $200 million.

Bendigo and Adelaide Bank reported a slight increase in its Common Equity Tier 1 ratio to 11.38% for the quarter ended March 2026, driven by net profit and capital inflows. Risk-weighted assets rose 1.75%, largely due to loan portfolio expansion and a new operational risk capital overlay.

General Capital Limited reported an 18% increase in revenue to $26.8 million for the year ended March 2026, while net profit after tax held steady at $2.7 million amid economic uncertainty and a goodwill impairment. The company declared a fully imputed final dividend, signalling confidence despite regulatory challenges.

The Australian Treasurer has mandated the disposal of over 1.6 billion shares held by foreign entities in Northern Minerals, intensifying regulatory scrutiny of foreign ownership in this critical rare earths company.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

The Takeovers Panel has declined Atlas Arteria’s bid to block Diamond Infraco from dispatching its takeover Bidder’s Statement, prolonging uncertainty over the contested offer.

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

Macquarie Bank Limited has posted a robust FY2026 result, with net profit attributable to ordinary equity holders soaring 74% to AUD 6.011 billion, underpinned by strong performances in its Banking and Financial Services and Commodities and Global Markets divisions.

Light & Wonder (ASX:LNW) posted modest revenue growth in 2025, driven by Gaming and iGaming segments, while SciPlay revenue dipped slightly. The company completed its Grover acquisition, settled a $128 million IP dispute with Aristocrat, and transitioned to a sole ASX listing.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.